- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02605655
Clinical Trial of Chinese Formula AMP-1915 on Metabolic Syndrome
Phase 0 Clinical Trial of Chinese Formula AMP-1915 on Metabolic Syndrome
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
In China, the herbal formulas have been used in the treatment of diabetes for centuries. Huangqisan, investigators named it AMP-1915, is one of traditional Chinese herbal formula used to relieve diabetes which was recorded in Shengji Zonglu (General Medical Collection of Royal Benevolence) published in 1117 A.D. AMP-1915 consists of three herbs: Radix Astragali (roots of Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) Hsiao, A), Mori Cortex radices (root barks of Morus alba L., M) and Puerariae Lobatae Radix (roots of Pueraria lobata (Willd.) Ohwi., P). Recent studies have shown that these three herbs and their constituents have therapeutic effects on the metabolic disorders.
This randomized, double-blind, placebo-controlled trial was conducted in a community hospital of Shanghai, China. 60 adult participants were metabolic disorder patients according with at least two impaired metabolic profiles (obesity, hyperglycemia, hyperlipidemia or others). During 3-month treatment, participants were randomly divided in to two groups assigned to take AMP-1915 or placebo. AMP-1915 or placebo was mixed into instant noodles as daily meals with same color, shape, size and packaging. BMI, fasting blood glucose (FBG), triglyceride (TG), total cholesterol (TCH), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), insulin, HbA1c were measured before and after treatment.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Prima fase 1
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Overweight (BMI >= 20) or
- Hyperglycemia (FBG>=6.7 mmol/l) or
- Hyperlipidemia (TG >=1.7 mmol/l or TCH>=5.72 mmol/l or HDL-c <=1.00 mmol/l or LDL-c>=3.12 mmol/l)
Exclusion Criteria:
-
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: AMP-1915
Instant noodles contained AMP-1915 2 g/pc with meal, 1 pc/day for 3 months.
|
A traditional Chinese Formula extract from Astragalus, Radix Puerariae and Cortex Mori is mixed into instant noodles.
Patients are treated with AMP-1915 as meal.
Altri nomi:
|
Comparatore placebo: Placebo
Instant noodles with the same sharp and color as Experimental noodles with meal, 1 pc/day for 3 months.
|
Instant noodles without drug
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Fasting blood glucose (FBG)
Lasso di tempo: Change from baseline FBG at 3 months
|
Patients' FBG from both placebo and AMP-1915-treated group was collected before treatment as a baseline and after 3-month treatment. The difference between these two time points presents the drug effect. |
Change from baseline FBG at 3 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Plasma lipid levels
Lasso di tempo: Change from baseline lipid levels at 3 months
|
Patients' blood from both placebo and AMP-1915-treated group was collected before treatment as a baseline and after 3-month treatment. Triglyceride (TG), total cholesterol (TCH), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c) were measured. The difference between these two time points presents the drug effect, separately. |
Change from baseline lipid levels at 3 months
|
Plasma Insulin concentration
Lasso di tempo: Change from baseline insulin concentration at 3 months
|
Patients' insulin concentration from both placebo and AMP-1915-treated group was collected before treatment as a baseline and after 3-month treatment. The difference between these two time points presents the drug effect. |
Change from baseline insulin concentration at 3 months
|
Body weight
Lasso di tempo: Change from baseline body weight at 3 months
|
Patients' body weight from both placebo and AMP-1915-treated group was measured before treatment as a baseline and after 3-month treatment. The difference between these two time points presents the drug effect. |
Change from baseline body weight at 3 months
|
Plasma HbA1c
Lasso di tempo: Change from baseline Plasma HbA1c at 3 months
|
Patients' Plasma HbA1c from both placebo and AMP-1915-treated group was measured before treatment as a baseline and after 3-month treatment. The difference between these two time points presents the drug effect. |
Change from baseline Plasma HbA1c at 3 months
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Guang Ji, MD, Shanghai University of TCM
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- ShanghaiUTCM-01
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Sindrome metabolica X
-
Markus KnuppMerian Iselin Klinik; Basel Academy for Quality and Research in MedicineReclutamento
-
Joint Authority for Päijät-Häme Social and Health...Tampere UniversityAttivo, non reclutante
-
University of California, DavisNational Institute of Mental Health (NIMH)CompletatoPremutazione X FragileStati Uniti
-
GE HealthcareCompletato
-
Central Hospital, Nancy, FranceNon ancora reclutamentoOgni intervento endoscopico utilizzando i raggi XFrancia
-
Alko Do Brasil Industria e Comercio LtdaSconosciutoEsami a raggi X del tratto gastrointestinale
-
Ramsay Générale de SantéDr Béatrice DaoudSconosciutoRaggi X di latta | Parenchima polmonareFrancia
-
The Catholic University of KoreaCompletatoSindrome metabolica X | Sindrome cardiovascolare metabolica | Sindrome da insulino-resistenza X | Sindrome dismetabolica XCorea, Repubblica di
-
Assuta Medical CenterCompletatoRaggi X; Effetti | Complicazioni delle procedure bariatricheIsraele
-
University Hospital, BrestCompletatoMisura della dose di raggi XFrancia
Prove cliniche su AMP-1915
-
IntegoGen, LLCRitiratoIdradenite SuppurativaStati Uniti
-
Sentient ResearchWayne State University; University of Mississippi Medical Center; AIDS Healthcare... e altri collaboratoriNon ancora reclutamento
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)CompletatoDisturbo ossessivo-compulsivoStati Uniti
-
San Diego State UniversityNational Institute of Mental Health (NIMH)CompletatoDisturbo d'ansia generalizzatoStati Uniti
-
Johns Hopkins UniversityCompletato
-
MedImmune LLCGlaxoSmithKlineCompletato
-
The University of Texas Health Science Center at...Completato
-
University of South AlabamaNon ancora reclutamentoMorbo di Parkinson | Sintomi depressivi
-
MedImmune LLCDaiichi Sankyo Co., Ltd.CompletatoArtrite reumatoideStati Uniti
-
Centre Hospitalier Universitaire, AmiensRitirato